A RETROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF INJECTION AUGMENTIN IN COVID-19 PATIENTS WITH PNEUMONIA AT A TERTIARY CARE TEACHING HOSPITAL, TELANGANA

AITHA SWETHA RANI; PUDUTHA MADHAVI; CHAKRADHAR T.

doi:10.22159/ijpps.2022v14i10.45730

Authors

AITHA SWETHA RANI Department of Pharmacology, Osmania Medical College Hyderabad https://orcid.org/0000-0001-9053-0184
PUDUTHA MADHAVI Department of Pharmacology, Osmania Medical College Hyderabad
CHAKRADHAR T. Department of Pharmacology, Osmania Medical College Hyderabad https://orcid.org/0000-0001-9053-0184

DOI:

https://doi.org/10.22159/ijpps.2022v14i10.45730

Keywords:

Covid-19 patients, Retrospective study

Abstract

Objective: Coronavirus is a single-stranded, enveloped, positive-sense RNA virus. It is responsible for the acute respiratory syndrome (SARS) and the disease is named COVID-19 by WHO. It is also called SARS-CoV-2. Pneumonia is one of the complications of COVID-19 disease. Patients with pneumonia admitted to General Hospital were treated with Augmentin. Augmentin is a broad-spectrum antibacterial that has been available for clinical use in a wide range of indications for over 20 y and is now used primarily in the treatment of respiratory tract infections. The main objective of our study is to evaluate the efficacy of Augmentin in COVID-19 patients with pneumonia in terms of beneficial effects after treatment.

Methods: The present study was a retrospective, observational, record-based study of the case sheets of COVID-19 patients with pneumonia. The statistical analysis was done using paired t-test.

Results: In our institution COVID-19 patients with pneumonia were treated with Tablet FAVIRAPIR and Injection AUGMENTIN. The results were calculated using paired t-test and the P-value was<0.0001, which is significant as it is less than 0.05. Therefore, the post-treatment outcome results showed a significant improvement in disease reduction.

Conclusion: The study concludes that the empirical treatment of COVID-19 patients with pneumonia using an appropriate antibiotic reduces further deterioration of patients with pneumonia due to complications and also protects the patients from acquired infections during the hospital stay.

Downloads

Download data is not yet available.

References

Zoumpourlis V, Goulielmaki M, Rizo E, Baliou S, Spandidos DA. The COVID-19 pandemic as a scientific and social challenge in the 21stcentury. Mol Med Rep. 2022;22(4):3035-48.

Abbasi Oshaghi E, Mirzaei F, Farahani F, Khodadadi I, Tayebinia H. Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings. International Journal of Surgery. 2020;79:143-53. doi: 10.1016/j.ijsu.2020.05.018.

White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother. 2004;53Suppl 1:i3-20. doi: 10.1093/jac/dkh050, PMID 14726431.

Alamin ASA, Kheder SI. Knowledge, attitudes and practices of prescribers towards antimicrobial stewardship at hospitals in Khartoum State – Sudan. J Med Inform Decis Mak. 2020;1(3):12-25. doi: 10.14302/issn.2641-5526.jmid-20-3494.

Kim HS. Do an altered gut microbiota and an associated leaky gut affect COVID-19 severity? mBio. 2021;12(1):3022-30. doi: 10.1128/mBio.03022-20, PMID 33436436.

Vaughn VM, Gandhi TN, Petty LA, Patel PK, Prescott HC, Malani AN. Empiric antibacterial therapy and community-onset bacterial Co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study. Clin Infect Dis. 2020;72(10):533-41.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20) 30566-3, PMID 32171076.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9. doi: 10.1172/JCI137244, PMID 32217835.

IACG. Available from: https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf?ua=1.final_report_EN.pdf. [Last accessed on 18 May 2020].

Vuichard Gysin D, Abbas M, Harbarth S. In-hospital COVID-19 outbreak investigation: A practical approach to root cause analysis. Intensive Crit Care Nurs. 2021;67:103132. doi: 10.1016/j.iccn.2021.103132, PMID 34483027.

Prokop M, van Everdingen W, van Rees Vellinga T, Quarles van Ufford H, Stöger L, Beenen L. CO-RADS: A categorical CT assessment scheme for patients suspected of having COVID-19-definition and evaluation. Radiology. 2020;296(2):E97-E104. doi: 10.1148/radiol.2020201473. PMID 32339082.

Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin Infect Dis. 2019;68(6):e1-e47. doi: 10.1093/cid/ciy866.

Tan SH, Ng TM, Tay HL, Yap MY, Heng ST, Loo AYX. A point prevalence survey to assess antibiotic prescribing in patients hospitalized with confirmed and suspected coronavirus disease 2019 (COVID-19). J Glob Antimicrob Resist. 2021;24:45-7. doi: 10.1016/j.jgar.2020.11.025, PMID 33307276.

Bwire GM. Coronavirus: why men are more vulnerable to COVID-19 than Women? SN Compr Clin Med. 2020;2(7):874-6. doi: 10.1007/s42399-020-00341-w, PMID 32838138.

Patterson JE. Antibiotic utilization: is there an effect on antimicrobial resistance? Chest. 2001;119(2) Suppl:426S-30S. doi: 10.1378/chest.119.2_suppl.426s. PMID 11171780.

Ang H, Sun X. Risk factors for multidrug-resistant Gram-negative bacteria infection in intensive care units: a meta-analysis. Int J Nurs Pract. 2018;24(4):e12644. doi: 10.1111/ijn.12644, PMID 29575345.

Vaughn VM, Gandhi TN, Petty LA, Patel PK, Prescott HC, Malani AN. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study. Clin Infect Dis. 2021;72(10):e533-41. doi: 10.1093/cid/ciaa1239, PMID 32820807.